SUNFLOWER(SZ:300111) Chang Jiang Shang Bao·2025-09-09 00:05Core Viewpoint - The company Sunflower (300111.SZ) announced a significant asset restructuring plan involving the acquisition of controlling stakes in two companies, which has led to a notable increase in its stock price prior to the announcement [1][4]. Group 1: Acquisition Details - Sunflower plans to acquire the controlling stake in Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. [1][4] - The company intends to raise matching funds for this acquisition, which is expected to constitute a major asset restructuring [4][5]. - The acquisition is still in the planning stage, and the valuations of the target companies have not been finalized [4][5]. Group 2: Stock Performance - On September 5, the trading day before the announcement, Sunflower's stock price surged by over 14%, closing with an increase of 11.96% [2][8]. - The stock was suspended from trading starting September 8 to ensure fair information disclosure and avoid abnormal price fluctuations [5]. Group 3: Financial Performance - Sunflower's financial performance has been under pressure, with a reported revenue of 144 million yuan in the first half of 2025, a year-on-year decrease of 8.33%, and a net profit of 1.16 million yuan, down 35.68% [2][11]. - The company has experienced declining revenues and profits since its peak in 2010, with significant fluctuations in financial performance over the years [10][11]. Group 4: Strategic Direction - Sunflower has previously indicated a desire to seek opportunities for external growth through various means [3]. - The current acquisition represents a cross-industry move into the semiconductor materials sector, which raises questions about the company's ability to successfully navigate this transition [3][12].